CN109602859B - 苗药廖氏化风丹在制备防治黑色素瘤药物中的应用 - Google Patents
苗药廖氏化风丹在制备防治黑色素瘤药物中的应用 Download PDFInfo
- Publication number
- CN109602859B CN109602859B CN201910049186.2A CN201910049186A CN109602859B CN 109602859 B CN109602859 B CN 109602859B CN 201910049186 A CN201910049186 A CN 201910049186A CN 109602859 B CN109602859 B CN 109602859B
- Authority
- CN
- China
- Prior art keywords
- melanoma
- medicine
- application
- dan
- huafeng
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 201000001441 melanoma Diseases 0.000 title claims abstract description 41
- 239000003814 drug Substances 0.000 title claims abstract description 26
- 229940079593 drug Drugs 0.000 title claims abstract description 7
- 238000002360 preparation method Methods 0.000 title claims description 8
- 239000006187 pill Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 11
- 230000022131 cell cycle Effects 0.000 abstract description 7
- 238000000338 in vitro Methods 0.000 abstract description 4
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 238000000684 flow cytometry Methods 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 23
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 10
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 229930012538 Paclitaxel Natural products 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 229960001592 paclitaxel Drugs 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 239000012488 sample solution Substances 0.000 description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 241000255789 Bombyx mori Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 241000402754 Erythranthe moschata Species 0.000 description 1
- 208000004929 Facial Paralysis Diseases 0.000 description 1
- 241000305491 Gastrodia elata Species 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 241000239226 Scorpiones Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241000746716 Typhonium Species 0.000 description 1
- 208000036826 VIIth nerve paralysis Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 229940115256 melanoma vaccine Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 201000010088 skin benign neoplasm Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8988—Gastrodia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/22—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/28—Mercury; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/36—Arsenic; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/55—Glands not provided for in groups A61K35/22 - A61K35/545, e.g. thyroids, parathyroids or pineal glands
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/646—Arachnids, e.g. spiders, scorpions, ticks or mites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/535—Perilla (beefsteak plant)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/538—Schizonepeta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8884—Arisaema, e.g. Jack in the pulpit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Insects & Arthropods (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Developmental Biology & Embryology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Animal Husbandry (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了苗药廖氏化风丹在制备防治黑色素瘤药物中的应用，通过在体外运用黑色素瘤细胞WM35、WM239检测发现，廖氏化风丹具有显著的抑制黑色素瘤作用，并通过流式细胞检测其在细胞周期方面的作用，结果表明廖氏化风丹对黑色素瘤细胞周期影响显著，并且药物浓度越高，其阻滞越明显，可作为防治黑色素瘤制剂，制备成药剂学上允许的口服液、注射剂、片剂、胶囊剂、滴丸剂等。
Description
技术领域
本发明属于生物学和医药学技术领域，具体涉及一种苗药廖氏化风丹在制备防治黑色素瘤药物中的应用。
背景技术
苗药廖氏化风丹，由贵州万胜药业有限责任公司生产制造，丸剂，其现有作用：息风镇痉，豁痰开窍。用于风痰闭阻、中风偏瘫、癫痫，面神经麻痹，口眼歪斜。主要成份包括天麻、全蝎、僵蚕、白附子、苍术、天南星、麝香等20余味中药材。朱红色的水丸，剖面显棕黄色；有强烈香气、味辛。
黑色素瘤是由皮肤或其他器官黑素细胞产生的肿瘤，是最具侵袭性的皮肤肿瘤。黑色素瘤在我国发病率虽然在肿瘤中的比重较少，但总体为上升趋势。目前恶性黑色素瘤的治疗方法包括化疗、靶向治疗、免疫治疗及放疗等，但是黑色素瘤对放疗、化疗不敏感，所以治疗效果并不乐观，生物免疫治疗例如黑色素瘤疫苗等大多还处于研发或临床试验阶段。因此，提高早期诊断率，寻找对黑色素瘤的有效治疗药物是目前的首要任务。
发明内容
本发明的目的是针对黑色素瘤治疗困难，寻找出新的治疗黑色素瘤效果显著的药物。
针对上述目的，本发明提供了一种苗药廖氏化风丹作为制备防治黑色素瘤药物中的应用。
本发明在体外运用黑色素瘤细胞WM35、WM239检测发现，廖氏化风丹具有显著的抑制黑色素瘤作用，并通过流式细胞检测其在细胞周期方面的作用，结果表明廖氏化风丹对黑色素瘤细胞周期影响显著，阻滞细胞周期于G2-M期，并且药物浓度越高，其阻滞越明显，可作为防治黑色素瘤药物。
本发明将廖氏化风丹直接制备成防治黑色素瘤的制剂或者与其他防治黑色素瘤的药物复配制备成防治黑色素瘤的复方制剂，其中所述的制剂可以采用药剂学上允许的口服液、注射剂、片剂、胶囊剂、滴丸剂中任意一种。
本发明的有益效果为：与廖氏化风丹的现有用途相比，发明人发现了廖氏化风丹对黑色素瘤具有良好的体外抑制作用，发现了此药的新用途。而廖氏化风丹是已上市的药物，能直接应用于人体而不再需要进行临床安全评估，具有很好的应用前景，可快速提高此产品的市场占有率。
附图说明
图1是不同浓度廖氏化风丹对人黑色素瘤细胞WM35增殖抑制率。
图2是不同浓度廖氏化风丹对人黑色素瘤细胞WM239增殖抑制率。
图3是不同浓度廖氏化风丹对人黑色素瘤细胞WM35周期的影响。
具体实施方式
下面结合附图和实施例对本发明进一步详细说明。
实施例1
苗药廖氏化风丹体外抗黑色素瘤细胞的活性测试
1、实验材料
样品溶液的配制：将廖氏化风丹用DMSO分别配制成浓度为50μg/mL、25μg/mL、12.5μg/mL、6.25μg/mL、3.125μg/mL的样品溶液。
5％MTT溶液的配制：称取MTT粉末0.5g，加入灭菌的PBS 100mL，60℃溶解，0.22μm过滤膜过滤除菌，4℃保存。
细胞系：人黑色素瘤细胞WM35、WM239均为贵州省中国科学院天然产物化学重点实验室保存。人黑色素瘤细胞WM35、WM239于37℃5％CO2培养箱中用含5％FBS的DMEM培养基培养。
DMEM培养基及胰酶购于Hycone公司，胎牛血清(FBS)购于上海启动元生物科技有限公司，四甲基偶氮哩盐(MTT)、二甲基亚飒(DMSO)购于北京索莱宝科技有限公司。
2、实验方法
MTT法测定不同浓度廖氏化风丹对黑色素瘤细胞抑制增殖作用
以5×103/孔的密度，将处于指数增殖期的人黑色素瘤细胞WM35、WM239分别接种于96孔板中，每孔190μL含5％FBS的DMEM培养基，培养24h后，每孔加入10μL含不同浓度廖氏化风丹的样品溶液，每个浓度设5个复孔。另设DMSO对照组和100nmol紫杉醇(PTX)阳性对照组。细胞置37℃培养箱内继续培养72h后，每孔加入20μL 5％MTT溶液，继续培养4h后，1200r离心10min，弃去上清，每孔加入160μL DMSO，置振荡仪上充分混匀，采用酶标仪，以570nm为测试波长，630nm为参考波长，测量各孔吸光度计算抑制率，结果见图1和图2。
图1和图2的结果表明，廖氏化风丹对人黑色素瘤细胞WM35、WM239的生长有显著的抑制作用，且廖氏化风丹对WM35和WM239细胞的生长抑制具有显著的浓度依赖性。人黑色素瘤细胞WM35在浓度为25μg/mL的药物浓度下，其抑制率大于90％，在浓度为12.5μg/mL时，其抑制率为60.59％，高于100nmol紫杉醇的抑制率59.48％，处理数据得出半数抑制浓度IC50值WM35:11.85±1.19。人黑色素瘤细胞WM239在浓度为25μg/mL的药物浓度下，其抑制率大于50％，同时高于100nmol紫杉醇的抑制率41.42％，处理数据得出半数抑制浓度IC50值WM239:20.75±2.58。
2、流式细胞仪测定细胞周期的变化
将人黑色素瘤细胞WM35接种于60mm的圆形培养皿，置于37℃培养箱6h待其贴壁，加入含不同浓度廖氏化风丹的样品溶液，终浓度分别为5μg/mL、10μg/mL、20μg/mL，对照组加等量的DMSO，于37℃5％CO2培养箱中培养，收集加药20h的细胞，用500μL体积浓度为75％的乙醇水溶液固定，50μg/mL PI碘化丙啶溶液(含100μg/mL RNase，由PBS缓冲液配制)染色30min，于流式细胞仪上做细胞周期分析，结果见图3。
图3的流式结果表明：廖氏化风丹对人黑色素瘤细胞WM35周期影响显著，阻滞细胞周期于G2-M期，并且药物浓度越高，其阻滞越明显。
由以上结果可知，廖氏化风丹在制备防治黑色素瘤药物或黑色素瘤细胞增殖抑制剂方面具有潜在价值。
Claims (2)
1.苗药廖氏化风丹在制备防治黑色素瘤药物中的应用。
2.根据权利要求1所述的苗药廖氏化风丹在制备防治黑色素瘤药物中的应用，其特征在于：所述药物的剂型为口服液、注射剂、片剂、胶囊剂、滴丸剂中任意一种。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910049186.2A CN109602859B (zh) | 2019-01-18 | 2019-01-18 | 苗药廖氏化风丹在制备防治黑色素瘤药物中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910049186.2A CN109602859B (zh) | 2019-01-18 | 2019-01-18 | 苗药廖氏化风丹在制备防治黑色素瘤药物中的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109602859A CN109602859A (zh) | 2019-04-12 |
| CN109602859B true CN109602859B (zh) | 2021-07-16 |
Family
ID=66017838
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910049186.2A Active CN109602859B (zh) | 2019-01-18 | 2019-01-18 | 苗药廖氏化风丹在制备防治黑色素瘤药物中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109602859B (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111773296B (zh) * | 2020-03-24 | 2021-09-03 | 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) | 康艾扶正复方在制备抗新型冠状病毒感染药物中的应用 |
| CN118384247A (zh) * | 2024-04-25 | 2024-07-26 | 贵州万胜药业有限责任公司 | 一种廖氏化风丹在制备胶质瘤药物中的应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1413704A (zh) * | 2002-11-19 | 2003-04-30 | 贵州万胜药业有限责任公司 | 化风丹 |
| CN1634410A (zh) * | 2004-11-01 | 2005-07-06 | 唐宗园 | 一种外用中药膏药 |
| CN1923232A (zh) * | 2005-09-01 | 2007-03-07 | 郑廷彬 | 一种用于祛风消痰、破瘀软坚的药物组合物及其制备方法和用途 |
| CN108392575A (zh) * | 2018-05-30 | 2018-08-14 | 贵州万胜药业有限责任公司 | 廖氏化风丹在制备抗白血病药物中的应用 |
-
2019
- 2019-01-18 CN CN201910049186.2A patent/CN109602859B/zh active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1413704A (zh) * | 2002-11-19 | 2003-04-30 | 贵州万胜药业有限责任公司 | 化风丹 |
| CN1634410A (zh) * | 2004-11-01 | 2005-07-06 | 唐宗园 | 一种外用中药膏药 |
| CN1923232A (zh) * | 2005-09-01 | 2007-03-07 | 郑廷彬 | 一种用于祛风消痰、破瘀软坚的药物组合物及其制备方法和用途 |
| CN108392575A (zh) * | 2018-05-30 | 2018-08-14 | 贵州万胜药业有限责任公司 | 廖氏化风丹在制备抗白血病药物中的应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109602859A (zh) | 2019-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Subhawa et al. | The effects of Houttuynia cordata Thunb and piper ribesioides wall extracts on breast carcinoma cell proliferation, migration, invasion and apoptosis | |
| CN108392575B (zh) | 廖氏化风丹在制备抗白血病药物中的应用 | |
| CN110946948A (zh) | 化风丹在制备抗乳腺癌药物中的应用 | |
| CN103352069B (zh) | 一种用于何首乌及其中药制剂肝毒性评价的生物毒性效价检定方法 | |
| CN109602859B (zh) | 苗药廖氏化风丹在制备防治黑色素瘤药物中的应用 | |
| CN105998171A (zh) | 秦艽及其提取物在制备治疗和/或预防皮肤癣的药物的用途 | |
| Mou et al. | Anti‐hepatitis B virus activity and hepatoprotective effect of des (rhamnosyl) verbascoside from Lindernia ruellioides in vitro | |
| Hu et al. | Aloin promotes oral squamous cell carcinoma cell apoptosis and autophagy through Akt/mTOR pathway | |
| CN105663100B (zh) | 药物芬戈莫德的用途 | |
| CN104277136A (zh) | 黄河滩枣多糖、其提取精制方法及应用 | |
| CN102961440B (zh) | 含有人环氧酶及天然阿霉素或类阿霉素的药用组合物、其制备方法及在制备多种药物的应用 | |
| CN105267250A (zh) | 二甲双胍联合黄酮治疗乳腺癌的应用及其产品 | |
| CN101333236A (zh) | 克力托辛的制备方法及在抗肿瘤药物中的应用 | |
| Wang et al. | Dangguibuxue Decoction Protects Against Lipopolysaccharides-Induced Mastitis in Bovine Mammary Epithelial Cells in Vitro | |
| CN118178565B (zh) | 廖氏化风丹在制备抗胃癌药物中的应用 | |
| CN113209075A (zh) | 二甲基柚皮素在制备用于预防和治疗癌症的药物中的应用 | |
| Wang et al. | Inhibitory Activity of Ficus deltoidea var. trengganuensis Aqueous Extract on Lipopolysaccharide‐Induced TNF‐α Production from Microglia | |
| LU505195B1 (en) | Use of Carvedilol in the Preparation of Drugs for the Treatment of Leukaemia | |
| CN102805768A (zh) | 一种猫爪草提取物在制备抗肺癌的药物中的应用 | |
| Zhang et al. | Yizhijiannao Granule and a combination of its effective monomers, icariin and Panax notoginseng saponins, inhibit early PC12 cell apoptosis induced by beta-amyloid (25–35)☆ | |
| CN104000839B (zh) | 假交替单胞菌胞外多糖在抑制乳腺癌细胞增殖中的应用 | |
| CN103877103A (zh) | Plcg1基因及其特异性抑制剂u73122抗辐射损伤的新用途 | |
| CN101983633A (zh) | 一种刺梨多糖的电离辐射防护新用途 | |
| CN107536837A (zh) | 一种细胞增效化合物的制备方法 | |
| CN105497108A (zh) | 黄芪在制备促进IFN-γ分泌的药物的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |